IGHE and Alzheimer disease: The results showed that subcutaneous injection of rmIL-38 promoting lesion scores and the symptoms of DNFB-induced AD, by increasing epidermal thickness, and the serum levels of IgE as well as the inflammatory infiltrate in AD-lesion (Figure S4A-G).